MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MaxCyte launched the CHANGE-seq-BE and ONE-seq-BE off-target nomination assays, available through its SeQure service to support the development of genome editing therapies. These assays provide sensitive identification of off-target sites for base editors (ABEs and CBEs), helping developers align with recent FDA guidance on genome safety and regulatory expectations.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.